Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Genetic ancestry: A new look at racial disparities in head and neck cancer

September 26, 2010 9:36 am | by EurekAlert | News | Comments

(Henry Ford Health System) Head and neck cancer outcomes associated with race may be more closely linked to social and behavioral factors than biological differences, especially for African-Americans, according to a new Henry Ford Hospital study. Researchers found that while those...

TOPICS:

Stress can control our genes

September 26, 2010 5:34 am | by EurekAlert | News | Comments

(University of Copenhagen) Researchers from Dr. Klaus Hansen's laboratory at BRIC, University of Copenhagen, have just shown that stress-factors can control our genes: Exposing human cells to a stress-activating compound turned on genes that are normally silenced. Protective...

TOPICS:

2010 AAO-HNSF new research daily highlights: Sunday, Sept. 26, 2010

September 26, 2010 5:34 am | by EurekAlert | News | Comments

(American Academy of Otolaryngology -- Head and Neck Surgery) Featuring more than 305 scientific research sessions, 594 posters and several hundred instruction course hours for attendees, the annual meeting is a unique opportunity for journalists from around the world to cover...

TOPICS:
Advertisement

Invensense IPO will change the competition in the motion sensing business

September 25, 2010 11:33 am | by I-Micronews | News | Comments

Business is there: moving from $300M in 2009 to $1.2B in 2015 only for smart phones

Duluth-Area Plasma Donors to be Recognized for Lifesaving Contribution in Fight Against Rare Diseases

September 25, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

DULUTH, Minn., Sept. 25 /- CSL Plasma , one of the world's largest collectors of human plasma, is honoring donors from the Duluth area today as part of a statewide observance of "Plasma Protein Therapies Month." According to Randy Furby, Senior Vice President and General Manager of CSL...

TOPICS:

HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients

September 25, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

NATICK, Mass., Sept. 25 /- Boston Scientific Corporation (NYSE: BSX ) today announced three-year follow-up data from the HORIZONS-AMI trial.  The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and The Medicines Company...

TOPICS:

Data from Multiple Clinical Trials of OrbusNeich's Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT ...

September 25, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 25 /- OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell (EPC) capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture...

TOPICS:

HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients

September 25, 2010 9:31 am | by Boston Scientific | News | Comments

NATICK, Mass., Sept. 25 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial.  The trial, sponsored by the Cardiovascular Research Foundation (CRF) wi

TOPICS:
Advertisement

Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardi...

September 25, 2010 7:31 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, Sept. 25 /- Today Astellas Pharma US, Inc. ("Astellas") announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or...

TOPICS:

Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials

September 24, 2010 4:33 pm | by U.S. Food & Drug Administration | News | Comments

Recall due to risks of embolic, thrombotic and other vascular serious adverse events.

AACR Applauds Appointment of Ellen V. Sigal, Ph.D., to the Patient-Centered Outcomes Research Institute Board of Governors

September 24, 2010 3:33 pm | by AACR | News | Comments

WASHINGTON, D.C. — The American Association for Cancer Research applauds the appointment of Ellen V. Sigal, Ph.D., chairperson and founder of the Friends of Cancer Research, to the board of governors for the new Patient-Centered Outcomes Research Institute (PCORI).

TOPICS:

AACR President-elect Testifies Before President’s Cancer Panel

September 24, 2010 3:31 pm | by AACR | News | Comments

WASHINGTON, D.C. — AACR President-elect Judy E. Garber, M.D., M.P.H., testified on Sept. 22 before the President's Cancer Panel, "The Future of Cancer Research: Accelerating Scientific Innovation." The panel is exploring progress achieved since the National Cancer Act of 1971, and...

TOPICS:

World's Most Precise Clocks Test Relativity

September 24, 2010 2:33 pm | Podcasts | Comments

The world's most precise clocks can reveal tiny time dilations predicted by Einstein's theory of relativity -- but that's not all. Tom O'Brian of the National Institute for Standards and Technology talks about using these precise clocks in everything from cell phones to satellites.

Defining Human Uniqueness In 'Almost Chimpanzee'

September 24, 2010 2:33 pm | Podcasts | Comments

Humans and chimpanzees share very similar genes -- some analyses peg the differences at just 1 percent. But in his book Almost Chimpanzee, science writer Jon Cohen focuses on our differences, from the way we eat and communicate to our susceptibilities to disease and aging.

Who Decides The Price Of Human Life?

September 24, 2010 2:33 pm | Podcasts | Comments

Personalized medicine promises to deliver more tailored health care. But what if a person's genes reveal he won't get much benefit from the only available treatment? Ethicist Leonard Fleck discusses the tough decisions Americans face in deciding whether to pay for others' expensive treatments.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading